Exploring Metabolic Signatures: Unraveling the Association with Obesity in Children and Adolescents
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Eligibility Criteria
2.3. Literature Search
2.4. Study Selection
2.5. Data Extraction, Outcomes, and Data Synthesis
2.6. Validity Assessment
2.7. Data Management and Synthesis
2.8. Ethical Considerations
3. Results
3.1. Characteristics of Included Studies
3.2. Obesity Outcomes and Their Association with Metabolites
3.2.1. Amino Acids and Obesity Outcomes
3.2.2. Lipids and Fatty Acids and Obesity Outcomes
3.2.3. Glycolysis-Related and Energy Metabolites and Obesity Outcomes
3.3. Metabolically Unhealthy Obesity Outcomes and Their Association with Metabolites
3.3.1. Apolipoproteins, Lipids, and Fatty Acids in Relation to Risk for Metabolic Syndrome
3.3.2. Amino Acids and Insulin Resistance
3.3.3. Energy Metabolism and Insulin Sensitivity
3.4. Risk of Bias Assessment
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- World Health Organization. Obesity and Overweight. Available online: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 5 February 2024).
- WHO. European Regional Obesity Report. 2022. Available online: https://www.who.int/europe/publications/i/item/9789289057738 (accessed on 5 February 2024).
- Kumar, S.; Kelly, A.S. Review of Childhood Obesity: From Epidemiology, Etiology, and Comorbidities to Clinical Assessment and Treatment. Mayo Clin. Proc. 2017, 92, 251–265. [Google Scholar] [CrossRef] [PubMed]
- Mathew, H.; Farr, O.M.; Mantzoros, C.S. Metabolic Health and Weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism 2016, 65, 73–80. [Google Scholar] [CrossRef] [PubMed]
- Hivert, M.F.; Perng, W.; Watkins, S.M.; Newgard, C.S.; Kenny, L.C.; Kristal, B.S.; Patti, M.E.; Isganaitis, E.; DeMeo, D.L.; Oken, E.; et al. Metabolomics in the developmental origins of obesity and its cardiometabolic consequences. J. Dev. Orig. Health Dis. 2015, 6, 65–78. [Google Scholar] [CrossRef] [PubMed]
- Regan, J.A.; Shah, S.H. Obesity Genomics and Metabolomics: A Nexus of Cardiometabolic Risk. Curr. Cardiol. Rep. 2020, 22, 174. [Google Scholar] [CrossRef]
- Bujak, R.; Struck-Lewicka, W.; Markuszewski, M.J.; Kaliszan, R. Metabolomics for laboratory diagnostics. J. Pharm. Biomed. Anal. 2015, 113, 108–120. [Google Scholar] [CrossRef]
- Schrimpe-Rutledge, A.C.; Codreanu, S.G.; Sherrod, S.D.; McLean, J.A. Untargeted Metabolomics Strategies-Challenges and Emerging Directions. J. Am. Soc. Mass. Spectrom. 2016, 27, 1897–1905. [Google Scholar] [CrossRef]
- Wang, R.; Li, B.; Lam, S.M.; Shui, G. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. J. Genet. Genom. 2020, 47, 69–83. [Google Scholar] [CrossRef]
- Ouchi, N.; Parker, J.L.; Lugus, J.J.; Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11, 85–97. [Google Scholar] [CrossRef]
- Rangel-Huerta, O.D.; Pastor-Villaescusa, B.; Gil, A. Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies. Metabolomics Off. J. Metabolomic Soc. 2019, 15, 93. [Google Scholar] [CrossRef]
- Handakas, E.; Lau, C.H.; Alfano, R.; Chatzi, V.L.; Plusquin, M.; Vineis, P.; Robinson, O. A systematic review of metabolomic studies of childhood obesity: State of the evidence for metabolic determinants and consequences. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2022, 23 (Suppl. S1), e13384. [Google Scholar] [CrossRef]
- Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; The PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015, 350, g7647. [Google Scholar] [CrossRef] [PubMed]
- Higgins, J.P.; Morgan, R.L.; Rooney, A.A.; Taylor, K.W.; Thayer, K.A.; Silva, R.A.; Lemeris, C.; Akl, E.A.; Bateson, T.F.; Berkman, N.D.; et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ. Int. 2024, 186, 108602. [Google Scholar] [CrossRef] [PubMed]
- Reinehr, T.; Wolters, B.; Knop, C.; Lass, N.; Hellmuth, C.; Harder, U.; Peissner, W.; Wahl, S.; Grallert, H.; Adamski, J.; et al. Changes in the serum metabolite profile in obese children with weight loss. Eur. J. Nutr. 2015, 54, 173–181. [Google Scholar] [CrossRef]
- Hellmuth, C.; Kirchberg, F.F.; Lass, N.; Harder, U.; Peissner, W.; Koletzko, B.; Reinehr, T. Tyrosine Is Associated with Insulin Resistance in Longitudinal Metabolomic Profiling of Obese Children. J. Diabetes Res. 2016, 2016, 2108909. [Google Scholar] [CrossRef]
- Hellmuth, C.; Kirchberg, F.F.; Brandt, S.; Moß, A.; Walter, V.; Rothenbacher, D.; Brenner, H.; Grote, V.; Gruszfeld, D.; Socha, P.; et al. An individual participant data meta-analysis on metabolomics profiles for obesity and insulin resistance in European children. Sci. Rep. 2019, 9, 5053. [Google Scholar] [CrossRef]
- Singh, A.; Kinnebrew, G.; Hsu, P.-C.; Weng, D.Y.; Song, M.-A.; Reisinger, S.A.; McElroy, J.P.; Keller-Hamilton, B.; Ferketich, A.K.; Freudenheim, J.L.; et al. Untargeted Metabolomics and Body Mass in Adolescents: A Cross-Sectional and Longitudinal Analysis. Metabolites 2023, 13, 899. [Google Scholar] [CrossRef]
- Mansell, T.; Magnussen, C.G.; Nuotio, J.; Laitinen, T.T.; Harcourt, B.E.; Bekkering, S.; McCallum, Z.; Kao, K.-T.; Sabin, M.A.; Juonala, M.; et al. Decreasing severity of obesity from early to late adolescence and young adulthood associates with longitudinal metabolomic changes implicated in lower cardiometabolic disease risk. Int. J. Obes. 2022, 46, 646–654. [Google Scholar] [CrossRef]
- Ojanen, X.; Cheng, R.; Törmäkangas, T.; Rappaport, N.; Wilmanski, T.; Wu, N.; Fung, E.; Nedelec, R.; Sebert, S.; Vlachopoulos, D.; et al. Towards early risk biomarkers: Serum metabolic signature in childhood predicts cardio-metabolic risk in adulthood. EBioMedicine 2021, 72, 1–10. [Google Scholar] [CrossRef]
- Hosking, J.; Pinkney, J.; Jeffery, A.; Cominetti, O.; Da Silva, L.; Collino, S.; Kussmann, M.; Hager, J.; Martin, F. Insulin Resistance during normal child growth and development is associated with a distinct blood metabolic phenotype (Earlybird 72). Pediatr. Diabetes 2019, 20, 832–841. [Google Scholar] [CrossRef]
- Monnerie, S.; Comte, B.; Ziegler, D.; Morais, J.A.; Pujos-Guillot, E.; Gaudreau, P. Metabolomic and Lipidomic Signatures of Metabolic Syndrome and its Physiological Components in Adults: A Systematic Review. Sci. Rep. 2020, 10, 669. [Google Scholar] [CrossRef]
- Aguilera, C.M.; Gil-Campos, M.; Cañete, R.; Gil, A. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin. Sci. 2008, 114, 183–193. [Google Scholar] [CrossRef] [PubMed]
- Ritter, O.; Jelenik, T.; Roden, M. Lipid-mediated muscle insulin resistance: Different fat, different pathways? J. Mol. Med. Berl. Ger. 2015, 93, 831–843. [Google Scholar] [CrossRef]
- Kelly, B.; Pearce, E.L. Amino Assets: How Amino Acids Support Immunity. Cell Metab. 2020, 32, 154–175. [Google Scholar] [CrossRef]
- Zhao, X.; Gang, X.; Liu, Y.; Sun, C.; Han, Q.; Wang, G. Using Metabolomic Profiles as Biomarkers for Insulin Resistance in Childhood Obesity: A Systematic Review. J. Diabetes Res. 2016, 2016, 8160545. [Google Scholar] [CrossRef]
- Handakas, E.; Keski-Rahkonen, P.; Chatzi, L.; Alfano, R.; Roumeliotaki, T.; Plusquin, M.; Maitre, L.; Richiardi, L.; Brescianini, S.; Scalbert, A.; et al. Cord blood metabolic signatures predictive of childhood overweight and rapid growth. Int. J. Obes. 2021, 45, 2252–2260. [Google Scholar] [CrossRef]
- Würtz, P.; Mäkinen, V.P.; Soininen, P.; Kangas, A.J.; Tukiainen, T.; Kettunen, J.; Savolainen, M.J.; Tammelin, T.; Viikari, J.S.; Rönnemaa, T.; et al. Metabolic Signatures of Insulin Resistance in 7,098 Young Adults. Diabetes 2012, 61, 1372–1380. [Google Scholar] [CrossRef]
- Mohorko, N.; Petelin, A.; Jurdana, M.; Biolo, G.; Jenko-Pražnikar, Z. Elevated serum levels of cysteine and tyrosine: Early biomarkers in asymptomatic adults at increased risk of developing metabolic syndrome. BioMed Res. Int. 2015, 2015, 418681. [Google Scholar] [CrossRef]
- Zhao, X.; Han, Q.; Liu, Y.; Sun, C.; Gang, X.; Wang, G. The Relationship between Branched-Chain Amino Acid Related Metabolomic Signature and Insulin Resistance: A Systematic Review. J. Diabetes Res. 2016, 2016, 2794591. [Google Scholar] [CrossRef]
- Guasch-Ferré, M.; Hruby, A.; Toledo, E.; Clish, C.B.; Martínez-González, M.A.; Salas-Salvadó, J.; Hu, F.B. Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2016, 39, 833–846. [Google Scholar] [CrossRef]
- Adams, S.H. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv. Nutr. Bethesda Md. 2011, 2, 445–456. [Google Scholar] [CrossRef]
- Walldius, G.; Jungner, I.; Aastveit, A.H.; Holme, I.; Furberg, C.D.; Sniderman, A.D. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin. Chem. Lab. Med. 2004, 42, 1355–1363. [Google Scholar] [CrossRef]
- Sellers, E.A.C.; Singh, G.R.; Sayers, S.M. Apo-B/AI ratio identifies cardiovascular risk in childhood: The Australian Aboriginal Birth Cohort study. Diabetes Vasc. Dis. Res. 2009, 6, 94–99. [Google Scholar] [CrossRef]
- Juonala, M.; Viikari, J.S.; Kähönen, M.; Solakivi, T.; Helenius, H.; Jula, A.; Marniemi, J.; Taittonen, L.; Laitinen, T.; Nikkari, T.; et al. Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: The cardiovascular risk in young Finns study. J. Am. Coll. Cardiol. 2008, 52, 293–299. [Google Scholar] [CrossRef]
- Piperi, C.; Kalofoutis, C.; Papaevaggeliou, D.; Papapanagiotou, A.; Lekakis, J.; Kalofoutis, A. The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease. Clin. Biochem. 2004, 37, 377–381. [Google Scholar] [CrossRef]
- Fischer, K.; Kettunen, J.; Würtz, P.; Haller, T.; Havulinna, A.S.; Kangas, A.J.; Soininen, P.; Esko, T.; Tammesoo, M.-L.; Mägi, R.; et al. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: An observational study of 17,345 persons. PLoS Med. 2014, 11, e1001606. [Google Scholar] [CrossRef]
- Lawler, P.R.; Akinkuolie, A.O.; Chandler, P.D.; Moorthy, M.V.; Vandenburgh, M.J.; Schaumberg, D.A.; Lee, I.-M.; Glynn, R.J.; Ridker, P.M.; Buring, J.E.; et al. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circ. Res. 2016, 118, 1106–1115. [Google Scholar] [CrossRef]
Variable | Definition |
---|---|
Population | Children and adolescents aged 2–19 years |
Exposure/Intervention | Metabolomics, metabolic signatures, and metabolic biomarkers |
Comparator | No intervention, any intervention, or standard care The absence of the exposure or a different level of exposure |
Outcome | Ov/Ob and MUO risk Association of metabolic signatures/biomarkers with obesity/adiposity/metabolic disorders/endocrine disorders |
Parameter | Inclusion Criteria for All Domains | Exclusion Criteria for All Domains |
---|---|---|
Participants | Human subjects | Animals Human subjects with monogenic disorders (e.g., MC4R deficiency, leptin deficiency, etc.), syndromic forms of obesity (e.g., Prader–Willi, Alstrom syndrome, etc.), or subjects receiving medication known to affect weight (antidepressants, antiepileptics, antipsychotics, mood stabilizers, antimanic agents, and corticosteroids) |
Age | 2 to 19 years old | <2 years old and >19 years old |
Article type | Peer-reviewed journal articles | Letters, editorials, study or review protocols, pre-prints |
Study area | Europe, USA, Canada, Oceania | Asia, Africa, South America |
Study design | Longitudinal prospective studies, randomized controlled trials with ≥12 months of follow-up, and meta-analyses of the above | Cross-sectional studies, controlled experiments, in vitro studies, in vivo animal studies, in silico studies, and scoping reviews |
Time of publication | 1 January 2013–3 July 2024 for original publications and 1 January 2018–3 July 2024 for meta-analyses | Original publications prior to 31 December 2012 and meta-analyses prior to 31 December 2017 |
Language | English | Non-English |
Study | Country | Study Design | Sample Size | Age, Mean ± SD | Follow-Up Period | Methodology | Key Metabolites Identified |
---|---|---|---|---|---|---|---|
Singh et al., 2023 [18] | USA | Longitudinal cohort study (Buckeye Teen Health Study) | 81 (100% males) | 16.08 ± 1.20 years | 1 year | UPLC-QTOF-MS (urine) | Glycylproline, 3’-Sialyllactose, Formiminoglutamic acid, 4-hydroxyproline, Citrulline, Inosine |
Mansell et al., 2022 [19] | Australia | Longitudinal cohort study (COBRA cohort) | 98 (52% males) | 10.3 ± 3.5 years | 5 years | NMR (serum) | XL-VLDL-L, L-VLDL-L, S-VLDL-L, ApoB/ApoA1, VLDL-C, MUFAs, MUFAs%, alanine, phenylalanine, tyrosine, pyruvate, glycoprotein acetyls, HDL-C, LA%, Omega-6%, PUFAs, Acetoacetate, 3-hydroxybutyrate |
Reinehr et al., 2014 [15] | Germany | Post hoc analysis of participants who underwent a lifestyle intervention (“Obeldicks”) within a non-randomized controlled trial | 160 (61.3% males) | 11 ± 2 years | 1 year | HPLC-MS (serum) | Glutamine, methionine, LPCaC18:1, LPCaC18:2, LPCaC20:4, PCaeC36:2 |
Hellmuth et al., 2019 [17] | Europe (multi) | Post hoc longitudinal analysis of biomarker changes over 2.5 years in participants from the CHOP study, a double-blind, randomized intervention trial | 396 (50% males) | 5.5 ± 0.07 years | 2.5 years | UPLC-QTOF-MS (serum) | Free carnitine, SM 32:2, SM 34:2, Carn 3:0 |
Ojanen et al., 2021 [20] | Finland | Longitudinal cohort study | 396 (0% males) | 11.2 ± 0.4 years | 7.5 years | NMR (serum) | ApoB/ApoA ratio, GlycAs |
Hellmuth et al., 2016 [16] | Germany | Post hoc analysis of participants who underwent a lifestyle intervention (“Obeldicks”) within a non-randomized controlled trial | 80 (45% males) | 11.5 ± 2.4 years | 1 year | HPLC-MS (serum) | Acylcarnitines, amino acids |
Hosking et al., 2019 [21] | UK, Switzerland | Longitudinal cohort study (EarlyBird cohort) | 190 [Study 1: 40 (50% males); Study 2: 150 (70% males)] | 4.8–5.1 years | Study 1: 9 years; Study 2: 11 years | 1H NMR (serum) | Amino acids, lipids, lactate |
Author, Year (Reference) | Outcomes | Statistical Analysis | Results |
---|---|---|---|
Singh et al., 2023 [18] | Significant metabolic features associated with positive change in BMI at 1-year follow-up. | Estimate (95% CI) based on a stratified linear regression model (age, race, BMI z-score, and total energy intake). | Glycylproline: −0.018 (−0.029, 0.007) p = 0.002, 3’-Sialyllactose: 0.009 (0.002, 0.016) p = 0.006, formiminoglutamic acid: 0.016 (0.004, 0.028) p = 0.008, glycylproline: −0.014 (−0.025, 0.003) p = 0.01, 4-hydroxyproline: 0.016 (0.003, 0.03) p = 0.016, Citrulline: 0.01 (0.002, 0.018) p = 0.013, 4-Vinylsyringol: −0.01 (−0.02, 0.001) p = 0.022, Citrulline: 0.012 (0.001, 0.023) p = 0.025, Inosine: 0.005 (0.0004, 0.01) p = 0.03, |
Mansell et al., 2022 [19] | Association of change in BMI from baseline to the end of follow-up (5.5 years) with the change in metabolomic profiles. | Coefficients (95% CI) [Benjamini–Hochberg adjusted p-value] of the change in log concentrations of metabolites in SD units decrease in BMI over time per unit (kg/m 2) from linear regression models adjusted for age at each time point and sex. | lipoprotein subclasses: XL-VLDL-L: −0.038 (−0.066 to −0.01), p = 0.04; L-VLDL-L: −0.038 (−0.066 to −0.01), p = 0.04; S-VLDL-L: −0.039 (−0.071 to −0.008), p = 0.05; Apolipoproteins: ApoB/ApoA1: −0.046 (−0.073 to −0.019), p = 0.01; cholesterols: VLDL-C: −0.035 (−0.062 to −0.008), p = 0.05; HDL-C: 0.045 (0.011 to 0.08), p = 0.04; HDL2-C: 0.049 (0.016 to 0.082), p = 0.02; fatty acids: unsaturation: 0.059 (0.022 to 0.097), p = 0.02; MUFAs: −0.041 (−0.068 to −0.014), p = 0.02; LA%: 0.065 (0.03 to 0.101), p = 0.01; Omega-6%: 0.069 (0.034 to 0.103), p = 0.003; PUFAs%: 0.065 (0.03 to 0.1), p = 0.01; MUFAs%: −0.061 (−0.094 to −0.028), p = 0.01; amino acids: alanine: −0.072 (−0.105 to −0.04), p = 0.002; phenylalanine: −0.069 (−0.102 to −0.037), p = 0.002; tyrosine: −0.068 (−0.099 to −0.037), p = 0.002; glycerides and phospholipids: total triglycerides: −0.043 (−0.069 to −0.016), p = 0.02; VLDL-TGs: -0.042 (−0.07 to −0.015), p = 0.02; TG/PG: −0.052 (−0.081 to −0.023), p = 0.01; glycolysis-related metabolites: pyruvate: −0.077 (−0.114 to −0.039), p = 0.002; ketone bodies: Acetoacetate: 0.065 (0.021 to 0.109), p = 0.02; 3-hydroxybutyrate: 0.066 (0.018 to 0.113), p = 0.04; inflammation: glycoprotein acetyls: −0.063 (−0.092 to −0.035), p = 0.002. Additional adjustment for pubertal status confirmed statistically significant associations for fatty acids: LA%, PUFAs%, and MUFAs%; amino acids: alanine, phenylalanine, and tyrosine; glycolysis-related metabolites: pyruvate; and inflammation: glycoprotein acetyls. |
Reinehr et al., 2014 [15] | Change in metabolites between groups (children with obesity with substantial weight loss and children with obesity without weight loss; all underwent a lifestyle intervention). | The 14 metabolites [glutamine, methionine, proline, nine phospholipids (PCaeC34:1, C34:2, C34:3, C36:2, C36:3, C38:2, LPCaC18:1, C18:2, and C20:4), and two acylcarnitines (C12:1 and C16:1)] were compared between baseline and 1-year follow-up. | The 14 metabolites did not change significantly in children without weight loss. In children with substantial weight loss, glutamine [mean (SD) at baseline: 567 (120), follow-up: 588 (102), p = 0.013], methionine [mean (SD) at baseline: 27 (6), follow-up: 29 (6), p = 0.026], LPCaC18:1 [mean (SD) at baseline: 10 (2.8), follow-up: 10.9 (3), p = 0.003], LPCaC18:2 [mean (SD) at baseline: 12.3 (5.2), follow-up: 13.5 (5.2), p = 0.035], LPCaC20:4 [mean (SD) at baseline: 19.6 (8.2), follow-up: 21.7 (7.7), p = 0.011] and PCaeC36:2 [mean (SD) at baseline: 4.5 (1.7), follow-up: 4.8 (1.4), p = 0.026] increased significantly, while the other eight metabolites did not change significantly. |
Hellmuth et al., 2019 [17] | Researchers used the metabolite concentrations at 5.5 years to predict the BMI z-score at 8 years of age in the CHOP study. | Linear regression models adjusted for child age and gender. | Plasma levels of free carnitine (p = 6.17 × 10−6), SM 32:2 (p = 2.16 × 10−4), SM 34:2 (p = 3.09 × 10−4) and Carn 3:0 (p = 4.09 × 10−2) were significantly positively associated with the BMI z-score at 8 years of age. However, after adjusting for the BMI z-score at 5.5 years, no metabolite reached the significance level. Regarding HOMA, glutamine at age 5.5 years was significantly negatively associated (p = 0.013/0.003) with HOMA indices at 8 years in both the unadjusted and adjusted linear models. NEFAs 26:1 (p = 0.012/0.015), 26:2 (p = 0.002/0.01), and 26:3 (p = 0.009/0.015) at age 5.5 years were significantly positively associated with HOMA indices at 8 years in both the unadjusted and adjusted linear models. Only serine levels remained significantly associated with HOMA in the adjusted model (p = 0.032). |
Ojanen et al., 2021 [20] | To assess cardiometabolic risk, a standardized continuously distributed variable for clustered metabolic risk (MetS score) was constructed. The risk score was calculated by standardizing and then summing the following continuously distributed metabolic traits: mean arterial pressure ([(2 × diastolic blood pressure) + systolic blood pressure]/3); abdominal fat mass; fasting plasma glucose; serum HDL cholesterol x −1; and fasting serum triglyceride z-score. The z-scores for each variable and MetS scores were calculated separately for each time point. A higher score indicated a higher cardiometabolic risk. | Regression analysis with MetS score as the dependent variable and metabolic biomarkers identified by LASSO as independent variables, after Bonferroni correction for multiple tests. | Baseline ApoB/ApoA ratio and GlycAs positively predicted while L-HDL-PLs negatively predicted 7.5-year Mets (r = 0.471 and p < 0.0001; r = 0.400 and p = 0.0005; and r = −0.465 and p < 0.0001, respectively, p: adjusted for multiple comparisons by Bonferroni). And 2-year ApoB/ApoA ratio and GlycAs positively predicted and L-HDL-PLs negatively predicted 7.5-year Mets (r = 0.449 and p < 0.0001; r = 0.440 and p < 0.0001; and r = −0.445 and p < 0.0001, respectively, p: adjusted for multiple comparisons by Bonferroni) only. ApoB/ApoA ratio, GlycAs, and L-HDL-PLs remained significant predictors of MetS score (p < 0.0001 for all). These associations were also robust to multi-covariate adjustment, including insulin, leptin, adiponectin, sex steroids, IGF-1, physical activity, and energy yield nutrient intakes. |
Hellmuth et al., 2016 [16] | Association of changes in metabolite concentrations with change in HOMA over the one-year intervention. | Change was defined as the relative change over the one-year intervention, with estimates reported alongside 95% confidence intervals (CIs). To assess the association between metabolites and markers of insulin resistance, a two-step robust regression approach was used. First, metabolite levels were adjusted for BMI using age- and sex-adjusted robust regression (M-estimator with Huber bi-square weighting). The residuals from this model were then regressed on the relative change in HOMA over the intervention period, using robust regression to minimize the influence of outliers. | All: Carn C0 1.10 [0.29; 1.90] p = 0.008, Carn C6:1-DC −0.33 [−0.59; −0.06] p = 0.015, Carn C6-oxo −0.24 [−0.43; −0.05] p = 0.014, Pro 0.81 [0.19; 1.40] p = 0.011; ratio of Carn C5/Carn C6-oxo 0.24 [0.07; 0.41] p = 0.007, ratio of Carn C6-oxo/xLeu −0.19 [−0.34; −0.03] p = 0.016, Tyr 0.79 [0.17; 1.40] p = 0.015; weight loss: AAA sum 1.04 [0.29; 1.80] p = 0.009, Carn C0 1.71 [0.88; 2.50] p < 0.001, Carn C3 0.49 [0.03; 0.96] p = 0.036; Carn C6:1-DC −0.29 [−0.47; −0.10] p = 0.003; Carn C6-oxo −0.21 [−0.35; −0.08] p = 0.003, Pro 0.72 [0.11; 1.30] p = 0.023, ratio of Carn C4/Carn C5-oxo 0.48 [0.18; 0.77] p = 0.0030, ratio of Carn C5/Carn C6-oxo 0.22 [0.08; 0.35] p = 0.002, ratio of Carn C6:1-DC/Carn C5:1 −0.22 [−0.41; −0.03] p = 0.024, ratio of Carn C6-oxo/xLeu −0.15 [−0.25; −0.04] p = 0.007, Trp 1.13 [0.14; 2.10] p = 0.027, Tyr 1.09 [0.51; 1.70] p = 0.001, Val 0.73 [0.07; 1.40] p = 0.033; no weight loss: ratio of Carn C5/Carn C6-oxo 0.29 [0.02; 0.57] p = 0.041. |
Hosking et al., 2019 [21] | Association between individual metabolites and IR (HOMA-IR), taking into account age, BMI z-scores, and physical activity. Study 1 was designed as a pilot study to explore whether HOMA-IR was associated with specific metabotypes. Study 2 aimed at replicating the observations in a higher number of children, and extending the analysis to the age of 16 years. | Coef (SE), Bonferroni-adjusted p-value of mixed effects models for the association between the metabolite and log IR over time. Adjusted for age, gender, BMI z-score, APHV (age at peak height velocity), MVPA (number of minutes spent in moderate-vigorous physical activity), and individual metabolites. | Study 1: Leucine [−0.103 (0.027), p = 0.01]; Valine [−0.107 (0.026), p = 0.003]; 3-D-hydroxybutyrate [−0.106 (0.027), p = 0.01]; alanine [0.085 (0.024), p = 0.03]; 3-D-hydroxybutyrate [−0.084 (0.024), p = 0.02]; citrate [−0.132 (0.028), p = 0.0002]; Creatine [−0.095 (0.029), p = 0.06]; phospholipids [−0.131 (0.031), p = 0.002]; Study 2: lipids (mainly LDL, fatty acid CH3 moieties) [0.108 (0.023), p = 0.0006]; Leucine [−0.121 (0.019), p = <0.0001]; Valine [−0.114 (0.02), p = <0.0001]; 2-Ketobutyrate [−0.071 (0.019), p = 0.024]; 3-D-hydroxybutyrate [−0.092 (0.018), p = <0.0001]; lipids (mainly LDL, fatty acids [CH2]n moieties) [0.133 (0.023), p = 0.00093]; lactate [0.101 (0.019), p = <0.0001]; alanine [0.156 (0.019), p = <0.0001]; lipids (mainly VLDL, fatty acids [CH2] moieties) [−0.12 (0.022), p = <0.0001]; Arginine [−0.116 (0.021), p = <0.0001]; Lysine [−0.112 (0.019), p = <0.0001]; glutamate [−0.112 (0.021), p = <0.0001]; 3-D-hydroxybutyrate [−0.118 (0.019), p = <0.0001]; glutamine [−0.118 (0.022), p = <0.0001]; citrate [−0.188 (0.021), p = <0.0001]; Asparagine [−0.115 (0.021), p = <0.0001]; Trimethylamine [−0.123 (0.022), p = <0.0001]; Dimethylglycine [−0.118 (0.021), p = <0.0001]; Lysine [−0.139 (0.02), p = <0.0001]; Creatine [−0.142 (0.023), p = <0.0001]; Citrulline [−0.137 (0.022), p = <0.0001]; Creatine [−0.121 (0.025), p = 0.00013]; serine [−0.134 (0.022), p = <0.0001]; Histidine [−0.136 (0.021), p = <0.0001]; Histidine [−0.124 (0.022), p = <0.0001]. When correcting for main covariates (gender, age, BMI z-scores, physical activity, and APHV), only the association between lactate and log IR remained significant. |
Study [Author, Year (Reference)] | Risk of Bias for Longitudinal Studies | |||||||
---|---|---|---|---|---|---|---|---|
D1 | D2 | D3 | D4 | D5 | D6 | D7 | Overall | |
Singh et al., 2023 [13] | ||||||||
Mansell et al., 2021 [14] | ||||||||
Reinehr et al., 2015 [15] | ||||||||
Hellmuth et al., 2019 [16] | ||||||||
Ojanen et al., 2021 [18] | ||||||||
Hellmuth et al., 2016 [21] | ||||||||
Hosking et al., 2019 [19] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Koutaki, D.; Stefanou, G.; Genitsaridi, S.-M.; Ramouzi, E.; Kyrkili, A.; Kontogianni, M.D.; Kokkou, E.; Giannopoulou, E.; Kassari, P.; Charmandari, E. Exploring Metabolic Signatures: Unraveling the Association with Obesity in Children and Adolescents. Nutrients 2025, 17, 1833. https://doi.org/10.3390/nu17111833
Koutaki D, Stefanou G, Genitsaridi S-M, Ramouzi E, Kyrkili A, Kontogianni MD, Kokkou E, Giannopoulou E, Kassari P, Charmandari E. Exploring Metabolic Signatures: Unraveling the Association with Obesity in Children and Adolescents. Nutrients. 2025; 17(11):1833. https://doi.org/10.3390/nu17111833
Chicago/Turabian StyleKoutaki, Diamanto, Garyfallia Stefanou, Sofia-Maria Genitsaridi, Eleni Ramouzi, Athanasia Kyrkili, Meropi D. Kontogianni, Eleni Kokkou, Eleni Giannopoulou, Penio Kassari, and Evangelia Charmandari. 2025. "Exploring Metabolic Signatures: Unraveling the Association with Obesity in Children and Adolescents" Nutrients 17, no. 11: 1833. https://doi.org/10.3390/nu17111833
APA StyleKoutaki, D., Stefanou, G., Genitsaridi, S.-M., Ramouzi, E., Kyrkili, A., Kontogianni, M. D., Kokkou, E., Giannopoulou, E., Kassari, P., & Charmandari, E. (2025). Exploring Metabolic Signatures: Unraveling the Association with Obesity in Children and Adolescents. Nutrients, 17(11), 1833. https://doi.org/10.3390/nu17111833